Full Year 2023 Financial Guidance:
We are updating our 2023 net sales and adjusted EPS guidance and reaffirming our 2023 adjusted EBITDA margin guidance as follows:
Projected Year Ending December 31, 2023 | Prior Guidance | Updated Guidance |
Net sales | $825M - $850M | $835M to $860M |
Adjusted EBITDA margin[2] | 13.5% - 14.0% | 13.5% - 14.0% |
Adjusted EPS[2] | $0.30 to $0.50 | $0.40 to $0.60 |
Conference Call
ZimVie will host a conference call today, May 3, 2023, at 4:30 p.m. ET to discuss its first quarter 2023 financial results. To access the call, please register online at https://investor.zimvie.com/events-presentations/event-calendar. A live and archived audio webcast will also be available on this site.
About ZimVie
ZimVie is a global life sciences leader in the dental and spine markets that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures and treat a wide range of spine pathologies. In March 2022, the company became an independent, publicly traded spin-off of the dental and spine business units of Zimmer Biomet to breathe new life, dedicated energy, and strategic focus to its portfolio of trusted brands and products.
https://finance.yahoo.com/news/zimvie-reports-first-quarter-2023-200500359.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.